Thinning HairNCT07195487
A Clinical Study to Evaluate the Safety, Effectiveness and In-Use Tolerability of Hair Growth and Scalp Health Serum in Subjects With Mild to Moderate Hair Thinning.
A study testing Fermented Extract Hair Growth and Scalp Health Serum in people with Thinning Hair, run by NovoBliss Research Pvt Ltd at 1 site in India.
Trial summary
This is a Prospective, Interventional, Randomized, Double-Blind, Placebo-Controlled, Single-Centre, Clinical Study to Evaluate the Safety, Efficacy and In-Use Tolerability of Fermented Extract Hair Growth and Scalp Health Serum. Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Thinning Hair
- What is being tested?
- Fermented Extract Hair Growth and Scalp Health Serum
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 34 participants
- Where
- 1 siteIndia
- Study dates
- 18 Nov 2025to 7 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age: 18-55years (both inclusive) at the time of consent.
- Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
- Females of childbearing potential must have a self-reported negative urine pregnancy.
- Subject is in good general health as determined by the Investigator on the basis of medical history.
- Patients must have a confirmed diagnosis of mild to moderate hair thinning, during clinical study and grade will be evaluated by the dermatologist by using Norwood-Hamilton classification for male (Grade 1-3) and Ludwig pattern scale for female (Grade 1-2) with active hair shredding
- Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.
Show all 12Show fewer
- If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
- Subjects are willing to give written informed consent and are willing to follow the study procedure.
- Subjects who commit not to use any other medicated/ prescription shampoos/hair care products, any other hair growth products or hair colour or dye, other than the test treatment for the entire duration of the study.
- Subject is willing and able to comply with study procedures, including all scheduled visits, treatment applications, and assessments.
- Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.
- Subject must be able to understand and provide written informed consent to participate in the study.
Who cannot join
- Subject have history of severe hair fall due to any clinically significant self-reported problems like anaemia, thyroid problems.
- Subject have history of any prior hair growth procedures done (e.g. hair transplant or laser).
- Subject who had taken topical product of hair loss for at least 4 weeks before enrolment.
- Subject who had taken any systemic product for any illnesses for at least 3 months.
- History of alcohol or drug addiction.
- Subject having history or resent condition of severely irritated or visibly inflamed scalp or severe scalp disease.
Show all 12Show fewer
- Subject having history or present condition of an allergic response to any cosmetic products, any other condition which could warrant exclusion from the study.
- Pregnant or breast feeding or planning to become pregnant during the study period.
- History of chronic illness which may influence the cutaneous state.
- Subject have participated any clinical research study related to hair care products.
- Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or product of any type of cancer within the last 6 months.
- Participants with advanced baldness (Norwood 4-7, Ludwig 3), long-standing bald patches (>1 year), scarring alopecia, active scalp infections, recent use of hair growth treatments (e.g., minoxidil or finasteride within the past 3 months), severe scalp conditions, or known allergies to any test product ingredients will be excluded.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Single-Center Clinical Study to Assess the Safety, Efficacy, and In-Use Tolerability of a Fermented Hair Growth and Scalp Health Serum in Subjects With Mild to Moderate Hair Thinning.
This is a Prospective, Interventional, Randomized, Double-Blind, Placebo-Controlled, Single-Centre, Clinical Study to Evaluate the Safety, Efficacy and In-Use Tolerability of Fermented Extract Hair Growth and Scalp Health Serum.
Read the detailed description
A total of 34 participants, including males and non- pregnant, non-lactating females aged between 18 and 55years (inclusive) with Mild to Moderate Hair Thinning will be enrolled in the study. The study aims to complete evaluation for 30 participants, from that 20 subjects in the Treatment A group (bioactive) and 10 subjects in the Treatment B group (placebo). Scalp skin type-categorized as dry, oily, or combination-will be recorded during screening.
There will be total of 6 visits during the study. The duration of the study will be 90 Days (3 months) from the enrolment Visit 01 (Day -04, Week 00): Screening, Informed Consent, Tattoo Marking, Hair Growth Rate Visit 02 (Day 01, Week 00): Randomization, Baseline Evaluations, Buccal DNA Swab Visit 03 (Day 42, Week 06): Tattoo Marking, Hair Growth Rate Visit 04 (Day 45, Week 06): Evaluation Visit 05 (Day 87, Week 12): Tattoo Marking, Hair Growth Rate Visit 06 (Day 90, Week 12): Evaluations, Buccal DNA Swab, End of Study Evaluation parameter: Hair Growth Rate, Thickness, Density, Scalp Condition, A:T Ratio, 60 secs Hair combing, Hair Pull Test, Dermatologist Evaluation, Subjective Response Index, Global Photography of Head Crown, Graying Severity Score (GSS), Tensile Strength
- Conditions
- Thinning Hair
- Being tested
- Fermented Extract Hair Growth and Scalp Health Serum, Placebo Hair Growth and Scalp Health Serum
- Medical subject headings
- Alopecia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fermented Extract Hair Growth and Scalp Health SerumOther
Mode of Usage: Apply the serum directly to the scalp using the rollerball applicator. Gently roll the ball over thinning or affected areas of the scalp. Gently massage the serum into the scalp with clean fingertips to help it absorb fully. Ensure liquid is visible on the scalp and reapply until you feel a cooling wet sensation during application - this confirms the mechanism is working and that a good amount of product is being delivered.
Frequency: Apply the treatment twice daily- once after morning shower and once before bed time. immediately after shower and at night before bed.
Route of administration: Topical Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight.
Placebo Hair Growth and Scalp Health SerumOther
Mode of Usage: Apply the serum directly to the scalp using the rollerball applicator. Gently roll the ball over thinning or affected areas of the scalp. Gently massage the serum into the scalp with clean fingertips to help it absorb fully. Ensure liquid is visible on the scalp and reapply until you feel a cooling wet sensation during application - this confirms the mechanism is working and that a good amount of product is being delivered.
Frequency: Apply the treatment twice daily - once after morning shower and once before bed time. immediately after shower and at night before bed.
Route of administration: Topical Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight
| Study group | Role | What they receive |
|---|---|---|
| Fermented Extract Hair Growth and Scalp Health Serum | Experimental | Mode of Usage: Apply the serum directly to the scalp using the rollerball applicator. Gently roll the ball over thinning or affected areas of the scalp. Gently massage the serum into the scalp with clean fingertips to help it absorb fully. Ensure liquid is visible on the scalp and reapply until you feel a cooling wet sensation during application - this confirms the mechanism is working and that a good amount of product is being delivered.
Frequency: Apply the treatment twice daily- once after morning shower and once before bed time. immediately after shower and at night before bed.
Route of administration: Topical Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight. Receives: Other: Fermented Extract Hair Growth and Scalp Health Serum |
| Placebo Hair Growth and Scalp Health Serum | Placebo comparator | Mode of Usage: Apply the serum directly to the scalp using the rollerball applicator. Gently roll the ball over thinning or affected areas of the scalp. Gently massage the serum into the scalp with clean fingertips to help it absorb fully. Ensure liquid is visible on the scalp and reapply until you feel a cooling wet sensation during application - this confirms the mechanism is working and that a good amount of product is being delivered.
Frequency: Apply the treatment twice daily - once after morning shower and once before bed time. immediately after shower and at night before bed.
Route of administration: Topical Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight Receives: Other: Placebo Hair Growth and Scalp Health Serum |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Hair Growth Rate measured by CASLiteNova from the tattoo-marked area
Hair growth rate will be assessed using the CASLiteNova from the tattoo-marked area of the scalp. The change from baseline values will be compared within and across treatment arms.
Measured: Baseline (Day -4 to Day 1, prior to treatment), Day 42 (±2 days), Day 45 (±2 days), Day 87 (±2 days), and Day 90 (±2 days).
Change from Baseline in Baby Hair Count and Hair Length measured by CASLiteNova from the bald scalp area
Baby hair count and hair length will be evaluated using the CASLiteNova digital imaging system from the bald scalp area. The change from baseline values will be compared within and across treatment arms.
Measured: Baseline (Day 1, prior to treatment), Day 45 (±2 days), and Day 90 (±2 days).)
Change from Baseline in Hair Density and Hair Thickness measured by CASLiteNova
Hair density (hairs/cm²) and hair thickness (μm) will be evaluated using the CASLiteNova digital imaging system. The change from baseline values will be compared within and across treatment arms.
Measured: Baseline (Day 1, prior to treatment), Day 45 (±2 days), and Day 90 (±2 days).
Secondary outcomes (12)
Change from Baseline in Scalp Condition measured by CASLiteNova
Scalp condition will be evaluated using the CASLiteNova digital imaging system to assess improvements in scalp parameters.
Measured: Baseline (Day 1, prior to treatment), Day 45 (±2 days), and Day 90 (±2 days).
Change from Baseline in Anagen-to-Telogen (A:T) Hair Ratio measured by CASLiteNova
The ratio of anagen to telogen hairs will be assessed using the CASLiteNova digital imaging system to evaluate hair growth phase distribution.s
Measured: Baseline (Day 1, prior to treatment), Day 45 (±2 days), and Day 90 (±2 days).
Change from Baseline in Total Hair Count on the Vertex Region measured by Digital Photography and Image Pro Analysis
Total hair count on the vertex (crown) region of the scalp will be evaluated using standardized digital photography at a 90° angle and analyzed through image pro analysis software.
Measured: Baseline (Day 1, prior to treatment), Day 45 (±2 days), and Day 90 (±2 days).
Change from Baseline in General Scalp Appearance evaluated by Dermatologist
General scalp appearance, including itchiness, redness, roughness, scaliness, and dryness, will be assessed by a dermatologist or a dermatologist-trained evaluator.
Measured: Baseline (Day 1, prior to treatment), Day 45 (±2 days), and Day 90 (±2 days).
Improvement in general appearance of hair i.e. hair volume, hair plasticity, hair density, hair shininess, hair smoothness, hair dryness and hair strength evaluated by the Dermatologist or Dermatologist trained evaluator
General hair appearance, including hair volume, plasticity, density, shininess, smoothness, dryness, and strength, will be assessed by a dermatologist or a dermatologist-trained evaluator.
Measured: Baseline (Day 01, prior to treatment usage) to post treatment assessments on Day 45 (+2 Days) and Day 90 (+2 Days)
Improvement in hair fall- both from the scalp root and due to hair shaft breakage evaluated through 60 second hair combing test by dermatologist trained evaluator
Hair fall, including shedding from the scalp root and hair shaft breakage, will be evaluated using the 60-second hair combing test by a dermatologist-trained evaluator.
Measured: Baseline (Day 01, prior to treatment usage) to post treatment assessments on Day 45 (+2 Days) and Day 90 (+2 Days)
Improvement in hair root strength evaluated through hair pull test by dermatologist trained evaluator
Hair root strength will be evaluated using the hair pull test by a dermatologist-trained evaluator.
Measured: Baseline (Day 01, prior to treatment usage) to post treatment assessments on Day 45 (+2 Days) and Day 90 (+2 Days)
Improvement in tensile strength of single hair strand evaluator through TESTRONIX tensile tester of hair
Tensile strength of a single hair strand will be measured using a TESTRONIX tensile tester to assess mechanical hair strength.
Measured: Baseline (Day 01, prior to treatment usage) to post treatment assessments on Day 45 (+2 Days) and Day 90 (+2 Days)
Improvement in extent of hair greying as measured by a Grey Scoring Scale
The extent of hair greying will be assessed using a validated Grey Scoring Scale to evaluate changes from baseline.
Measured: Baseline (Day 01, prior to treatment usage) to post treatment assessments on Day 90 (+2 Days)
Change from Baseline in Scalp Microbiome Composition measured by 16S rRNA Gene-Based DNA Sequencing
Scalp microbiome will be assessed using BD swabs for 16S rRNA gene-based DNA sequencing to evaluate changes in microbial composition from baseline.
Measured: Baseline (Day 1, prior to treatment) and Day 90 (±2 days).
Change from Baseline in Treatment Perception Questionnaire Score measured by Structured Questionnaire
Treatment perception will be evaluated using a structured questionnaire. Scores will be compared with baseline values to assess patient-reported outcomes.
Measured: Baseline (Day 1, prior to treatment), Day 45 (±2 days), and Day 90 (±2 days).
Change from Baseline in Hair Density Patterns measured by Norwood-Hamilton Scale (males) and Ludwig Scale (females)
Hair density patterns will be assessed using the Norwood-Hamilton scale for male participants and the Ludwig scale for female participants. Changes from baseline will be evaluated.
Measured: Baseline (Day 1, prior to treatment) and Day 90 (±2 days).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2025
- Study start18 Nov 2025
- Primary completion7 Apr 2026
- Study completion7 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thinning HairStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- NovoBliss Research Pvt Ltd
- Sponsor type
- University, hospital or other
- Collaborators
- Blossom Microbiotics LLC
- Responsible party
- Sponsor
- Investigators
- Nayan Patel, Study director, NovoBliss Research Pvt Ltd
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07195487
- Sponsor's protocol ID
- NB250022-BM_1.0_10Sep25
- Status last verified
- Nov 2025
- First submitted
- 12 Sep 2025
- Last updated
- 30 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Single-Center Clinical Study to Assess the Safety, Efficacy, and In-Use Tolerability of a Fermented Hair Growth and Scalp Health Serum in Subjects With Mild to Moderate Hair Thinning.
- ClinicalTrials.gov ID
- NCT07195487
- Acronym / sponsor ID
- NB250022-BM_1.0_10Sep25
- Conditions
- Thinning Hair
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- NovoBliss Research Pvt LtdUniversity, hospital or other
- Collaborators
- Blossom Microbiotics LLC
- Study start
- 18 Nov 2025 (actual)
- Primary completion
- 7 Apr 2026 (actual)
- Study completion
- 7 Apr 2026 (actual)
- First posted
- 26 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Prospective, Interventional, Randomized, Double-Blind, Placebo-Controlled, Single-Centre, Clinical Study to Evaluate the Safety, Efficacy and In-Use Tolerability of Fermented Extract Hair Growth and Scalp Health Serum.
Detailed description
A total of 34 participants, including males and non- pregnant, non-lactating females aged between 18 and 55years (inclusive) with Mild to Moderate Hair Thinning will be enrolled in the study. The study aims to complete evaluation for 30 participants, from that 20 subjects in the Treatment A group (bioactive) and 10 subjects in the Treatment B group (placebo). Scalp skin type-categorized as dry, oily, or combination-will be recorded during screening.
There will be total of 6 visits during the study. The duration of the study will be 90 Days (3 months) from the enrolment Visit 01 (Day -04, Week 00): Screening, Informed Consent, Tattoo Marking, Hair Growth Rate Visit 02 (Day 01, Week 00): Randomization, Baseline Evaluations, Buccal DNA Swab Visit 03 (Day 42, Week 06): Tattoo Marking, Hair Growth Rate Visit 04 (Day 45, Week 06): Evaluation Visit 05 (Day 87, Week 12): Tattoo Marking, Hair Growth Rate Visit 06 (Day 90, Week 12): Evaluations, Buccal DNA Swab, End of Study Evaluation parameter: Hair Growth Rate, Thickness, Density, Scalp Condition, A:T Ratio, 60 secs Hair combing, Hair Pull Test, Dermatologist Evaluation, Subjective Response Index, Global Photography of Head Crown, Graying Severity Score (GSS), Tensile Strength
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Fermented Extract Hair Growth and Scalp Health Serum | Experimental | Other: Fermented Extract Hair Growth and Scalp Health SerumMode of Usage: Apply the serum directly to the scalp using the rollerball applicator. Gently roll the ball over thinning or affected areas of the scalp. Gently massage the serum into the scalp with clean fingertips to help it absorb fully. Ensure liquid is visible on the scalp and reapply until you feel a cooling wet sensation during application - this confirms the mechanism is working and that a good amount of product is being delivered. Frequency: Apply the treatment twice daily- once after morning shower and once before bed time. immediately after shower and at night before bed. Route of administration: Topical Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight. |
| Placebo Hair Growth and Scalp Health Serum | Placebo comparator | Other: Placebo Hair Growth and Scalp Health SerumMode of Usage: Apply the serum directly to the scalp using the rollerball applicator. Gently roll the ball over thinning or affected areas of the scalp. Gently massage the serum into the scalp with clean fingertips to help it absorb fully. Ensure liquid is visible on the scalp and reapply until you feel a cooling wet sensation during application - this confirms the mechanism is working and that a good amount of product is being delivered. Frequency: Apply the treatment twice daily - once after morning shower and once before bed time. immediately after shower and at night before bed. Route of administration: Topical Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (12 listed)
- Age: 18-55years (both inclusive) at the time of consent.
- Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
- Females of childbearing potential must have a self-reported negative urine pregnancy.
- Subject is in good general health as determined by the Investigator on the basis of medical history.
- Patients must have a confirmed diagnosis of mild to moderate hair thinning, during clinical study and grade will be evaluated by the dermatologist by using Norwood-Hamilton classification for male (Grade 1-3) and Ludwig pattern scale for female (Grade 1-2) with active hair shredding
Key exclusion criteria (12 listed)
- Subject have history of severe hair fall due to any clinically significant self-reported problems like anaemia, thyroid problems.
- Subject have history of any prior hair growth procedures done (e.g. hair transplant or laser).
- Subject who had taken topical product of hair loss for at least 4 weeks before enrolment.
- Subject who had taken any systemic product for any illnesses for at least 3 months.
- History of alcohol or drug addiction.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fermented Extract Hair Growth and Scalp Health SerumMode of Usage: Apply the serum directly to the scalp using the rollerball applicator. Gently roll the ball over thinning or affected areas of the scalp. Gently massage the serum into the scalp with clean fingertips to help it absorb fully. Ensure liquid is visible on the scalp and reapply until you feel a cooling wet sensation during application - this confirms the mechanism is working and that a good amount of product is being delivered. Frequency: Apply the treatment twice daily- once after morning shower and once before bed time. immediately after shower and at night before bed. Route of administration: Topical Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight. | Other | Fermented Extract Hair Growth and Scalp Health Serum |
| Placebo Hair Growth and Scalp Health SerumMode of Usage: Apply the serum directly to the scalp using the rollerball applicator. Gently roll the ball over thinning or affected areas of the scalp. Gently massage the serum into the scalp with clean fingertips to help it absorb fully. Ensure liquid is visible on the scalp and reapply until you feel a cooling wet sensation during application - this confirms the mechanism is working and that a good amount of product is being delivered. Frequency: Apply the treatment twice daily - once after morning shower and once before bed time. immediately after shower and at night before bed. Route of administration: Topical Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight | Other | Placebo Hair Growth and Scalp Health Serum |
Primary outcome
Change from Baseline in Hair Growth Rate measured by CASLiteNova from the tattoo-marked area
Time frame: Baseline (Day -4 to Day 1, prior to treatment), Day 42 (±2 days), Day 45 (±2 days), Day 87 (±2 days), and Day 90 (±2 days).
Hair growth rate will be assessed using the CASLiteNova from the tattoo-marked area of the scalp. The change from baseline values will be compared within and across treatment arms.
Change from Baseline in Baby Hair Count and Hair Length measured by CASLiteNova from the bald scalp area
Time frame: Baseline (Day 1, prior to treatment), Day 45 (±2 days), and Day 90 (±2 days).)
Baby hair count and hair length will be evaluated using the CASLiteNova digital imaging system from the bald scalp area. The change from baseline values will be compared within and across treatment arms.
Change from Baseline in Hair Density and Hair Thickness measured by CASLiteNova
Time frame: Baseline (Day 1, prior to treatment), Day 45 (±2 days), and Day 90 (±2 days).
Hair density (hairs/cm²) and hair thickness (μm) will be evaluated using the CASLiteNova digital imaging system. The change from baseline values will be compared within and across treatment arms.
12 secondary outcomes
Change from Baseline in Scalp Condition measured by CASLiteNova
Time frame: Baseline (Day 1, prior to treatment), Day 45 (±2 days), and Day 90 (±2 days).
Change from Baseline in Anagen-to-Telogen (A:T) Hair Ratio measured by CASLiteNova
Time frame: Baseline (Day 1, prior to treatment), Day 45 (±2 days), and Day 90 (±2 days).
Change from Baseline in Total Hair Count on the Vertex Region measured by Digital Photography and Image Pro Analysis
Time frame: Baseline (Day 1, prior to treatment), Day 45 (±2 days), and Day 90 (±2 days).
Change from Baseline in General Scalp Appearance evaluated by Dermatologist
Time frame: Baseline (Day 1, prior to treatment), Day 45 (±2 days), and Day 90 (±2 days).
Improvement in general appearance of hair i.e. hair volume, hair plasticity, hair density, hair shininess, hair smoothness, hair dryness and hair strength evaluated by the Dermatologist or Dermatologist trained evaluator
Time frame: Baseline (Day 01, prior to treatment usage) to post treatment assessments on Day 45 (+2 Days) and Day 90 (+2 Days)
Improvement in hair fall- both from the scalp root and due to hair shaft breakage evaluated through 60 second hair combing test by dermatologist trained evaluator
Time frame: Baseline (Day 01, prior to treatment usage) to post treatment assessments on Day 45 (+2 Days) and Day 90 (+2 Days)
Improvement in hair root strength evaluated through hair pull test by dermatologist trained evaluator
Time frame: Baseline (Day 01, prior to treatment usage) to post treatment assessments on Day 45 (+2 Days) and Day 90 (+2 Days)
Improvement in tensile strength of single hair strand evaluator through TESTRONIX tensile tester of hair
Time frame: Baseline (Day 01, prior to treatment usage) to post treatment assessments on Day 45 (+2 Days) and Day 90 (+2 Days)
Improvement in extent of hair greying as measured by a Grey Scoring Scale
Time frame: Baseline (Day 01, prior to treatment usage) to post treatment assessments on Day 90 (+2 Days)
Change from Baseline in Scalp Microbiome Composition measured by 16S rRNA Gene-Based DNA Sequencing
Time frame: Baseline (Day 1, prior to treatment) and Day 90 (±2 days).
Change from Baseline in Treatment Perception Questionnaire Score measured by Structured Questionnaire
Time frame: Baseline (Day 1, prior to treatment), Day 45 (±2 days), and Day 90 (±2 days).
Change from Baseline in Hair Density Patterns measured by Norwood-Hamilton Scale (males) and Ludwig Scale (females)
Time frame: Baseline (Day 1, prior to treatment) and Day 90 (±2 days).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Thinning Hair
Not yet recruitingPhase 2
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia
Androgenetic Alopecia
RecruitingPhase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
Alopecia Areata
RecruitingPhase 1/2
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female
RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Alopecia Areata
Active, not recruiting
Evaluation of the Scalp Skin Care Effects of Premium Revitalizing Elixir and Topical 5% Minoxidil
Scalp Health, Alopecia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nayan Patel study director
NovoBliss Research Pvt Ltd
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fermented Extract Hair Growth and Scalp Health Serum in people with Thinning Hair, run by NovoBliss Research Pvt Ltd at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in Hair Growth Rate measured by CASLiteNova from the tattoo-marked area (time frame: Baseline (Day -4 to Day 1, prior to treatment), Day 42 (±2 days), Day 45 (±2 days), Day 87 (±2 days), and Day 90 (±2 days).). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2026.